Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Elicio Therapeutics (ELTX) Return on Sales (2020 - 2023)

Elicio Therapeutics filings provide 4 years of Return on Sales readings, the most recent being 0.43% for Q1 2023.

  • On a quarterly basis, Return on Sales fell 35.0% to 0.43% in Q1 2023 year-over-year; TTM through Mar 2023 was 0.43%, a 42.0% decrease, with the full-year FY2022 number at 0.12%, down 10.0% from a year prior.
  • Return on Sales hit 0.43% in Q1 2023 for Elicio Therapeutics, down from 0.15% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.06% in Q4 2020 to a low of 0.54% in Q1 2021.
  • Median Return on Sales over the past 4 years was 0.13% (2020), compared with a mean of 0.17%.
  • Biggest five-year swings in Return on Sales: soared 45bps in 2022 and later plummeted -35bps in 2023.
  • Elicio Therapeutics' Return on Sales stood at 0.06% in 2020, then tumbled by -91bps to 0.01% in 2021, then crashed by -2684bps to 0.15% in 2022, then plummeted by -188bps to 0.43% in 2023.
  • The last three reported values for Return on Sales were 0.43% (Q1 2023), 0.15% (Q4 2022), and 0.01% (Q3 2022) per Business Quant data.